Agomab (AGMB)
15.78
+0.95 (6.41%)
Upcoming Events
Latest Headlines
Agomab to Participate in Upcoming Investor Conferences
September 3, 2026 4:05 PM - StreetInsider
Piper Sandler Starts Agomab Therapeutics (AGMB) at Overweight
August 25, 2026 4:06 AM - StreetInsider
Cantor Fitzgerald Starts Agomab Therapeutics (AGMB) at Overweight
August 19, 2026 6:13 AM - StreetInsider
Form 6-K Agomab Therapeutics NV For: Aug 10
August 10, 2026 4:19 PM - SEC Filing
Agomab proposes two new board members ahead of shareholder vote
August 10, 2026 4:08 PM - StreetInsider
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
August 10, 2026 4:08 PM - StreetInsider
Agomab proposes two new board members ahead of shareholder vote
August 10, 2026 4:07 PM - StreetInsider
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
August 10, 2026 4:07 PM - Globe NewsWire
Form 6-K Agomab Therapeutics NV For: Aug 06
August 6, 2026 4:08 PM - SEC Filing
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
August 6, 2026 4:01 PM - StreetInsider
B.Riley Starts Agomab Therapeutics (AGMB) at Buy
July 23, 2026 8:23 AM - StreetInsider
Form 6-K Agomab Therapeutics NV For: Jun 23
June 23, 2026 4:14 PM - SEC Filing
Agomab outlines Phase 2b trial design for Crohn's disease drug
June 23, 2026 4:05 PM - StreetInsider
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
June 23, 2026 4:05 PM - StreetInsider
H.C. Wainwright Starts Agomab Therapeutics (AGMB) at Buy
June 22, 2026 6:07 AM - StreetInsider
Full Article List
